EPAM Systems Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, amendments to governance documents, and several compensation and incentive plan proposals. All Board-backed proposals passed, while a shareholder proposal for easier special meeting rights was rejected.
-
Q1 delivered strong revenue and profitability, led by AI-native growth and EMEA performance. Full-year guidance was lowered due to macro uncertainty and client delays, but a robust pipeline of large AI-enabled deals and ongoing cost optimization support confidence in H2 growth.
-
The organization is executing a comprehensive AI-driven transformation, integrating consulting and engineering to deliver scalable, industry-specific solutions and expanding its global delivery footprint. Financial guidance targets steady revenue growth, margin expansion, and strong free cash flow, supported by ongoing investments in talent, technology, and strategic partnerships.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong revenue growth, robust AI-native service momentum, and industry recognition. 2026 guidance anticipates continued growth, with a -1% headwind from a large client, ongoing investments in AI, and improving gross margins.
-
Q3 2025 delivered double-digit revenue growth, driven by AI-native services and strong execution across most verticals. Profitability and cash flow reached record levels, with improved guidance for full-year growth and margins. AI initiatives and proprietary IP continue to differentiate offerings.
-
Q2 2025 saw double-digit revenue growth, broad-based across all verticals and regions, with strong momentum in AI-native services and continued margin focus. Full-year guidance was raised, and the CEO transition remains on track.
-
Q1 delivered double-digit revenue growth and outperformance, driven by strong AI-related demand and client returns for quality execution. Guidance for 2025 was raised, with continued momentum expected despite macro uncertainty and a planned CEO transition in September.
Fiscal Year 2024
-
Q4 and full-year 2024 results exceeded expectations, with strong organic and inorganic growth, especially in financial services, life sciences, and AI-driven programs. 2025 guidance anticipates 10%-14% revenue growth, ongoing margin pressures from talent and GenAI investments, and improving profitability in the second half.
-
Q3 2024 results exceeded expectations with revenue growth, improved margins, and strong cash flow. Major acquisitions, including NEORIS, expanded global reach, while GenAI initiatives and client engagement drove optimism for future growth.
-
Q2 2024 revenue declined 2% year-over-year, with strong growth in healthcare and life sciences offset by declines in other verticals. The demand environment is stable but cautious, with no improvement expected for the rest of 2024. Investments in GenAI and global delivery expansion continue.